Abstract
In the last few years three new oral anticoagulants-Dabigatran, Rivaroxaban and Apixaban and two new antiplatelet agents Prasugrel and Ticagrelor have been approved for use. Dabigatran, Rivaroxaban and Apixaban have been approved for the prevention of stroke and systemic embolism in non valvular Atrial Fibrillation in the United States. Rivaroxaban is also approved for the prevention and treatment of venous thromboembolism, including pulmonary embolism. These drugs have been shown to be non-inferior to Warfarin. These drugs do not need monitoring and have lesser drug interactions compared to Warfarin. The newer antiplatelet agents Prasugrel and Ticagrelor are more potent than Clopidogrel and are more effective in patients with CYP2 C19 enzyme deficiency. Both of these drugs are approved in acute coronary syndrome and Prasugrel is approved only in acute coronary syndrome with percutaneous coronary intervention.
Keywords: Apixaban, cardiovascular diseases, Dabigatran, newer antiplatelet agents, newer oral anticoagulants, Prasugrel, Rivaroxaban, thromboembolism, Ticagrelor.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Review of Newer Anticoagulants and Anti-platelet Agents in Acute Coronary Syndrome and Cardiovascular Diseases
Volume: 11 Issue: 3
Author(s): Sucheta Gosavi and Debabrata Mukherjee
Affiliation:
Keywords: Apixaban, cardiovascular diseases, Dabigatran, newer antiplatelet agents, newer oral anticoagulants, Prasugrel, Rivaroxaban, thromboembolism, Ticagrelor.
Abstract: In the last few years three new oral anticoagulants-Dabigatran, Rivaroxaban and Apixaban and two new antiplatelet agents Prasugrel and Ticagrelor have been approved for use. Dabigatran, Rivaroxaban and Apixaban have been approved for the prevention of stroke and systemic embolism in non valvular Atrial Fibrillation in the United States. Rivaroxaban is also approved for the prevention and treatment of venous thromboembolism, including pulmonary embolism. These drugs have been shown to be non-inferior to Warfarin. These drugs do not need monitoring and have lesser drug interactions compared to Warfarin. The newer antiplatelet agents Prasugrel and Ticagrelor are more potent than Clopidogrel and are more effective in patients with CYP2 C19 enzyme deficiency. Both of these drugs are approved in acute coronary syndrome and Prasugrel is approved only in acute coronary syndrome with percutaneous coronary intervention.
Export Options
About this article
Cite this article as:
Gosavi Sucheta and Mukherjee Debabrata, Review of Newer Anticoagulants and Anti-platelet Agents in Acute Coronary Syndrome and Cardiovascular Diseases, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (3) . https://dx.doi.org/10.2174/18715257113119990084
DOI https://dx.doi.org/10.2174/18715257113119990084 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypertensive Pharmacogenomics in African Americans
Current Pharmacogenomics Hypersensitivity Reactions to Ophthalmic Products
Current Pharmaceutical Design Synthetic Thioamide, Benzimidazole, Quinolone and Derivatives with Carboxylic Acid and Ester Moieties: A Strategy in the Design of Antituberculosis Agents
Current Medicinal Chemistry A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery Complement and Microglia in the Neuropathogenesis of HIV Infection: Pro- and Anti-Inflammatory Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A New Binding Site Involving the C-terminal Domain to Design Specific Inhibitors of PepX
Protein & Peptide Letters Unusual Food Allergy: AlioideaAllergic Reactions Overview
Recent Patents on Inflammation & Allergy Drug Discovery Isolated Tongue Angioedema after Alteplase Infusion in Acute Ischemic Stroke
Current Drug Safety Editorial (Hot Topic: Inflammation, Coagulation, Vascular Permeability and Thrombosis)
Current Vascular Pharmacology New Insights on the Possible Role of Mast Cells in Aspirin-Induced Asthma
Current Molecular Pharmacology Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
Current Molecular Medicine Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Current Drug Therapy Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology A Discussion of Natural Rubber Latex Allergy with Special Reference to Children: Clinical Considerations
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design Challenges in the Management of Severe Asthma: Role of Current and Future Therapies
Current Pharmaceutical Design Healthcare Management During A Pandemic: The Other Side of the Coin for the Treatment of COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry